Pharmacy Benefits Management – Page 2

September 20, 2024

FDA Approves Miplyffa for the Treatment of Niemann-Pick Disease Type C

Sept. 20, 2024 – Zevra Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Miplyffa^TM (arimoclomol) capsules as an orally delivered treatment for Niemann-Pick disease type C (NPC).

September 17, 2024

Bionpharma Inc. Issues Voluntary Nationwide Recall of Atovaquone Oral Suspension Due to Bacterial Contamination

September 17, 2024 – Bionpharma Inc. is voluntarily recalling (1) single Batch (2310083) of Atovaquone Oral Suspension, 750mg per mL to the consumer level.

September 13, 2024

FDA Approves Ocrevus Zunovo. A Twice-A-Year Subcutaneous Injection for PeopleWith Relapsing and Progressive Multiple Sclerosis

September 13, 2024 – Genentech, announced the U.S. Food and Drug Administration (FDA) approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS)

September 13, 2024

FDA Approves Ebglyss for the Treatment of Atopic Dermatitis-

September 13, 2024 – Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) approved Ebglyss (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds

September 12, 2024

FDA Approves Tecentriq Hybreza Anti-PD-(L)1 Cancer Immunotherapy

September 12, 2024 – Genentech announced the U.S. Food and Drug Administration (FDA) approved Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs). The first and only PD-(L)1 inhibitor for subcutaneous (SC), under the skin injection for patients in the United States.

September 5, 2024

FDA Approves Boruzu Ready-to-Use Injection for Multiple Myeloma and MantleCell Lymphoma

September 5, 2024 – Amneal Pharmaceuticals, Inc. and Shilpa Medicare Limited announced the U.S. Food and Drug Administration (FDA) approval of Boruzu, a new presentation of bortezomib for ready-to-use subcutaneous or intravenous (IV) administration.

August 2, 2024

FDA Grants Accelerated Approval for Tecelra Cell Therapy for the Treatment of Synovial Sarcoma

August 01, 2024 - Adaptimmune Therapeutics plc announced U.S. Food and Drug Administration (FDA) accelerated approval of Tecelra